Q2 EPS Estimate for Kymera Therapeutics Raised by Analyst

Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) - Analysts at Leerink Partnrs upped their Q2 2025 earnings per share (EPS) estimates for shares of Kymera Therapeutics in a note issued to investors on Monday, June 2nd. Leerink Partnrs analyst F. Khurshid now anticipates that the company will earn ($1.08) per share for the quarter, up from their previous estimate of ($1.18). The consensus estimate for Kymera Therapeutics' current full-year earnings is ($2.79) per share. Leerink Partnrs also issued estimates for Kymera Therapeutics' Q3 2025 earnings at ($1.12) EPS, Q4 2025 earnings at ($1.23) EPS, FY2025 earnings at ($4.25) EPS and FY2026 earnings at ($4.76) EPS.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last issued its earnings results on Friday, May 9th. The company reported ($0.82) EPS for the quarter, beating analysts' consensus estimates of ($0.92) by $0.10. The business had revenue of $22.10 million during the quarter, compared to analysts' expectations of $11.38 million. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. The company's quarterly revenue was up 114.6% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.69) earnings per share.

Other equities research analysts have also issued research reports about the stock. Stifel Nicolaus initiated coverage on shares of Kymera Therapeutics in a report on Tuesday, May 20th. They issued a "buy" rating and a $55.00 price objective for the company. JPMorgan Chase & Co. increased their target price on Kymera Therapeutics from $57.00 to $64.00 and gave the stock an "overweight" rating in a research note on Tuesday. Citigroup assumed coverage on shares of Kymera Therapeutics in a research report on Thursday, March 13th. They set a "buy" rating and a $52.00 price target on the stock. B. Riley upgraded shares of Kymera Therapeutics from a "neutral" rating to a "buy" rating and lifted their price objective for the company from $38.00 to $60.00 in a report on Tuesday. Finally, Morgan Stanley raised shares of Kymera Therapeutics from an "equal weight" rating to an "overweight" rating and raised their price target for the company from $49.00 to $79.00 in a research report on Tuesday. Two investment analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Kymera Therapeutics has a consensus rating of "Moderate Buy" and an average price target of $59.82.

Kymera Therapeutics Price Performance

Shares of NASDAQ:KYMR traded down $0.04 during midday trading on Thursday, hitting $47.62. The company had a trading volume of 986,878 shares, compared to its average volume of 610,447. Kymera Therapeutics has a twelve month low of $19.45 and a twelve month high of $53.27. The stock has a market cap of $3.10 billion, a price-to-earnings ratio of -20.35 and a beta of 2.07. The business's 50-day simple moving average is $29.81 and its 200-day simple moving average is $35.74.

Insider Activity

In other Kymera Therapeutics news, Director Elena Ridloff sold 12,000 shares of the stock in a transaction that occurred on Tuesday, June 3rd. The shares were sold at an average price of $46.10, for a total value of $553,200.00. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, Director Jeffrey W. Albers sold 6,349 shares of the company's stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of $49.00, for a total transaction of $311,101.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 48,349 shares of company stock worth $2,334,301. 16.01% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Kymera Therapeutics

Several large investors have recently bought and sold shares of KYMR. Blue Trust Inc. increased its position in shares of Kymera Therapeutics by 74.8% during the fourth quarter. Blue Trust Inc. now owns 631 shares of the company's stock worth $25,000 after purchasing an additional 270 shares in the last quarter. KBC Group NV grew its stake in Kymera Therapeutics by 53.8% during the 4th quarter. KBC Group NV now owns 2,151 shares of the company's stock worth $87,000 after buying an additional 752 shares during the last quarter. Rhumbline Advisers grew its stake in Kymera Therapeutics by 3.0% during the 4th quarter. Rhumbline Advisers now owns 64,157 shares of the company's stock worth $2,581,000 after buying an additional 1,861 shares during the last quarter. Bank of New York Mellon Corp increased its position in Kymera Therapeutics by 4.5% during the fourth quarter. Bank of New York Mellon Corp now owns 127,093 shares of the company's stock worth $5,113,000 after buying an additional 5,448 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its stake in Kymera Therapeutics by 5.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 387,187 shares of the company's stock valued at $15,577,000 after buying an additional 20,346 shares during the last quarter.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.